Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omeprazole + clarithromycin + amoxicillin is a fixed-dose combination therapy used primarily for the eradication of Helicobacter pylori (H. pylori) infection and the treatment and prevention of duodenal or gastric ulcers associated with H. pylori. Omeprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, while amoxicillin is an aminopenicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. The combination works synergistically to both suppress stomach acid (improving ulcer healing and antibiotic efficacy) and eradicate H. pylori infection[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omeprazole + clarithromycin + amoxicillin.